BioDelivery Sciences International Inc. (NASDAQ:BDSI)’s share price was down 1.6% during mid-day trading on Monday . The stock traded as low as $2.38 and last traded at $2.40, with a volume of 221,565 shares changing hands. The stock had previously closed at $2.44.

Several equities analysts have recently issued reports on BDSI shares. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Cantor Fitzgerald downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and cut their price objective for the company from $9.00 to $5.00 in a report on Wednesday, May 11th. Piper Jaffray Cos. restated a “sell” rating and set a $4.00 price objective on shares of BioDelivery Sciences International in a report on Wednesday, August 10th. FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Finally, Janney Montgomery Scott restated a “hold” rating and set a $4.00 price objective on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $8.25.

The stock’s market cap is $130.34 million. The company has a 50 day moving average price of $2.55 and a 200 day moving average price of $2.87.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). The company earned $5 million during the quarter, compared to analysts’ expectations of $3.35 million. During the same quarter in the previous year, the business posted ($0.37) EPS. The business’s quarterly revenue was up 194.1% compared to the same quarter last year. Equities analysts forecast that BioDelivery Sciences International Inc. will post ($1.14) earnings per share for the current fiscal year.

In other news, Director William B. Stone sold 16,000 shares of BioDelivery Sciences International stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $2.57, for a total value of $41,120.00. Following the completion of the transaction, the director now owns 122,675 shares in the company, valued at approximately $315,274.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.